Lv71
4910 积分 2026-03-31 加入
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
3小时前
已完结
Non-invasive tests: Establishing efficacy for metabolic dysfunction–associated steatohepatitis beyond the biopsy—Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration
11天前
已完结
Transient elastography in acute hospital inpatients with harmful alcohol use: a service evaluation
23天前
已关闭
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
1个月前
已关闭
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
1个月前
已完结
Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial
1个月前
已完结
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
1个月前
已关闭
Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
1个月前
已完结
Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults, 2011-2020
1个月前
已完结
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
1个月前
已完结
皖公网安备34019202002308
